Toshio Shimizu

Professor, Early Phase 1 Drug Development Service, Department of New Experimental Therapeutics, Kansai Medical University Hospital. Osaka Japan

[Toshio Shimizu @ToshioShim1025]

https://t.co/3T9zPJGHcQ

[Toshio Shimizu @ToshioShim1025]

https://t.co/NZKPjfdvsp
Updated our website

[International Lung Cancer Summit @LungSummit]

Phase I study suggests that the ADC, Dato-DXd, showed promising antitumor activity & a manageable safety profile in heavily pretreated patients with advanced #NSCLC 🫁

See the #OpenAccess study in @JCO_ASCO by Toshio Shimizu, Rebecca Heist & colleagues ➡️ https://t.co/1eojdjdqZ6

[Toshio Shimizu @ToshioShim1025]

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 https://t.co/fDWGtxSBL5

[Herbert Loong, MBBS, FASCO @herbloong]

#HappeningNow! Come join us at our @APODDC #ClinicalTrials webinar series w/ Dr. Toshio Shimizu chairing this morning! Pleased to be able to bring @saxotomy from @NtuhTw & Dr. Jun Sato from #NationalCancerCenterJapan to share on practical issues of trial designs. @danieltanmd

[APODDC @apoddc]

📸 Some screenshots from our 2nd session of the #ClinicalTrialsDesign #webinar series earlier - picturing our host Prof. Toshio Shimizu, speakers Dr. Tom Wei-Wu Chen and Dr. Jun Sato. We hope to see you soon in our next session!